CTIS2024-511041-19-00进行中（未招募）1 期
A Phase 2b, Randomized, Active-Controlled, Double-Blind, Dose-Ranging Clinical Study to Evaluate a Switch to Islatravir (ISL) and MK-8507 Once-Weekly in Adults with HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once-Daily - MK-8591-013
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 161
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Is HIV-1 positive with plasma HIV-1 RNA <50 copies/mL at screening, Has been virologically suppressed on BIC/FTC/TAF for =6 months, Has a screening CD4+ T-cell count >200 cells/mm^3 (completed by the central laboratory), Is male or female, at least 18 years of age, at the time of signing the informed consent, Female participants are eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: a) is not a woman of childbearing potential (WOCBP), or b) is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis)
排除标准
- •Has HIV-2 infection, Is female and expecting to conceive or donate eggs at any time during the study, Has hypersensitivity or other contraindication to any of the components of the study interventions as determined by the investigator, Has active hepatitis C virus (HCV) coinfection (defined as detectable HCV RNA) or hepatitis B virus (HBV) coinfection (defined as hepatitis B surface antigen [HBsAg]-positive or HBV deoxyribonucleic acid [DNA] positive), Has a current (active) diagnosis of acute hepatitis due to any cause, Has a history of malignancy =5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or cutaneous Kaposi's sarcoma, Has a history or current evidence of any condition (including active tuberculosis infection), therapy, laboratory abnormality or other circumstance (including drug or alcohol use or dependence) that might, in the opinion of the investigator, confound the results of the study or interfere with the participant's participation for the full duration of the study, Is taking or is anticipated to require systemic immunosuppressive therapy, immune modulators, or any prohibited therapies, Is currently participating in or has participated in a clinical study with an investigational compound or device from 45 days prior to Day 1 through the study treatment period, Has a documented or known virological resistance to ulonivirine or nucleoside/nucleotide reverse transcriptase inhibitors (NNRTI)
研究者
相似试验
已完成
2 期
Dose Ranging, Switch Study of ISL and MK‑8507 Once-Weekly2024-511041-19-00Merck Sharp & Dohme LLC48
进行中（未招募）
1 期
Study to find at least one dose of BMS-955176 that will be safe, effective and tolerable in HIV-1 infected treatment naive adultsEUCTR2013-005487-26-DEViiV Healthcare UK Limited300
进行中（未招募）
1 期
Study to find at least one dose of BMS-955176 that will be safe, effective and tolerable in HIV-1 infected treatment naive adultsHIVMedDRA version: 18.0Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2013-005487-26-GBBristol-Myers Squibb International Corporation300
进行中（未招募）
1 期
Study to find at least one dose of BMS-955176 that will be safe, effectiveand tolerable in HIV-1 infected treatment naive adultsEUCTR2013-005487-26-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO300
进行中（未招募）
1 期
Study to find at least one dose of BMS-955176 that will be safe, effective and tolerable in HIV-1 infected treatment naive adultsHIVMedDRA version: 18.0Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2013-005487-26-ESBristol-Myers Squibb International Corporation300